<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjeev Krishna, MA, BMChB, DPhil, FRCP, ScD, FMedSci</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andreas Lindner, MD, MSc, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Veerle Lejon, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 11, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites [<a href="#rid1">1-3</a>]. There are two forms of the disease: an acute form occurring mainly in East and Southern Africa and caused by <em>Trypanosoma brucei rhodesiense</em> (rhodesiense HAT) and a more chronic form occurring mainly in West and Central Africa caused by <em>Trypanosoma brucei gambiense</em> (gambiense HAT) (<a class="graphic graphic_table graphicRef85846" href="/z/d/graphic/85846.html" rel="external">table 1</a>) [<a href="#rid3">3</a>]. These two <em>T. brucei</em> parasite subspecies have identical morphologic appearances and both are transmitted by tsetse flies (<em>Glossina</em>). However, the two forms of HAT differ in epidemiology, clinical presentation, and management. </p><p>Other salivarian trypanosomes cause animal trypanosomosis, including <em>Trypanosoma brucei</em>, <em>Trypanosoma evansi</em>, <em>Trypanosoma equiperdum</em>, <em>Trypanosoma vivax,</em> and <em>Trypanosoma congolense</em>.</p><p>The epidemiology, pathogenesis, clinical manifestations, and diagnosis of HAT will be reviewed here. The treatment and prevention of HAT are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H1921913034"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H3694704443"><span class="h2">Disease distribution</span><span class="headingEndMark"> — </span>There are two forms of HAT: a typically acute form occurring mainly in East and Southern Africa and caused by <em>T. b. rhodesiense</em> (rhodesiense HAT), and a more chronic form occurring mainly in West and Central Africa caused by <em>T. b. gambiense </em>(gambiense HAT) [<a href="#rid3">3</a>]. Gambiense HAT primarily affects humans in endemic areas, whereas rhodesiense HAT is primarily a zoonosis that only occasionally affects humans. Wild animals are the main reservoir for <em>T. b. rhodesiense</em> infection. </p><p>Sleeping sickness is endemic in 36 sub-Saharan African countries within the distribution of the tsetse fly [<a href="#rid4">4</a>]. There are an estimated 55 million people at various levels of risk for infection; cases have been mapped at the village level since 2000 (<a class="graphic graphic_figure graphicRef129080" href="/z/d/graphic/129080.html" rel="external">figure 1</a>) [<a href="#rid5">5-8</a>]. Countries particularly affected include the Democratic Republic of Congo, South Sudan, Angola, Guinea, and the Central African Republic (all of which have gambiense HAT); Uganda (which has both gambiense and rhodesiense HAT, but in different zones); and Tanzania, Malawi, and Zambia (which have rhodesiense HAT) [<a href="#rid9">9-13</a>]. In 2022, rhodesiense HAT re-emerged in Ethiopia after 31 years.</p><p>The disease distribution differs between the countries and is markedly focal in different parts of a single country. From 2018 to 2022, the distribution was as follows [<a href="#rid14">14</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Around 60 percent of cases occur in the Democratic Republic of the Congo. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following countries had 10 to 100 new reported cases: Angola, Central African Republic, Chad, Congo, Gabon, Guinea, Malawi, and South Sudan.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following countries have had sporadic cases (&lt;10 per year): Burkina Faso, Cameroon, Côte d'Ivoire, Equatorial Guinea, Ethiopia, Ghana, Kenya, Nigeria, Uganda, United Republic of Tanzania, Zambia, and Zimbabwe.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The following countries have had no new reported cases for over a decade: Benin, Botswana, Burundi, , The Gambia, Guinea Bissau, Liberia, Mali, Mozambique, Namibia, Niger, Rwanda, Senegal, Sierra Leone, Swaziland, and Togo.</p><p></p><p>HAT mainly affects marginalized and poor communities in remote areas. Such populations are exposed to the tsetse fly through daily activities on rivers, agriculture, animal husbandry, or hunting. The occurrence of HAT in a region often reflects war, civil unrest, and lack of a reliable presence of state authority. Therefore, nearly by definition, HAT as a public health problem occurs in areas where there is no research infrastructure; thus, many important questions of clinical and operational research remain unanswered.</p><p>Additional risk groups include (1) individuals who have resided in endemic areas for extended periods (eg, during a business stay, forestry work, or humanitarian mission) and (2) migrants and refugees; these individuals may present several years after leaving an endemic area, due to the slow progression of gambiense HAT [<a href="#rid15">15</a>]. </p><p>Between 2000 and 2010, 94 cases of HAT were reported in nonendemic countries; of these, 72 percent were cases of rhodesiense HAT imported from Tanzania, Malawi, Zambia, Zimbabwe, and Uganda [<a href="#rid15">15,16</a>]. Most affected individuals were short-term tourists exposed in national parks, game reserves, or areas near Lake Victoria. Reports have described clusters of infection among European tourists [<a href="#rid17">17-19</a>], highlighting the potential for emergence of this disease in international travelers. If a case of rhodesiense HAT is identified in a group of tourists, special attention should be given to the occurrence of additional cases in the group given the likelihood of shared exposure [<a href="#rid15">15</a>]. </p><p class="headingAnchor" id="H3365540705"><span class="h2">Epidemics</span><span class="headingEndMark"> — </span>In the last century, there have been three severe epidemics of HAT [<a href="#rid4">4</a>]: one between 1896 and 1906 (mostly in Uganda and the Congo Basin), one in the 1920s (in several Central African countries; arrested with systematic screening of at-risk individuals by mobile teams), and one that began in 1970 and lasted until the late 1990s. </p><p>The disease practically disappeared between 1960 and 1965, and surveillance was relaxed. Civil wars, displacement of people, economic difficulties, and slackening in vector control measures allowed re-emergence of disease in several foci. In 1998, almost 40,000 cases of HAT were reported, with an estimate of 300,000 additional undiagnosed cases [<a href="#rid4">4,5,20</a>]. Major efforts of the national control programs, with the support of the World Health Organization (WHO), bilateral co-operations, and nongovernmental organizations have led to a significant decline of HAT cases since the beginning of the 21<sup>st</sup> century [<a href="#rid4">4</a>]. In 2009, the number of reported cases was below 10,000 for the first time in 50 years. HAT (mostly gambiense HAT [&gt;87 percent]) occurrence fell below 1000 cases in 2018, remaining below that threshold as of 2022. [<a href="#rid7">7,8,14</a>] (<a class="graphic graphic_figure graphicRef130331" href="/z/d/graphic/130331.html" rel="external">figure 2</a>).</p><p class="headingAnchor" id="H1791542146"><span class="h2">Life cycle</span><span class="headingEndMark"> — </span>Humans are the main reservoir for <em>T. b. gambiense</em>; this species can also be found in some animals, including pigs. It is possible that animal reservoirs and latent human infections contribute to maintaining the gambiense reservoir [<a href="#rid21">21</a>]. Wild game animals and cattle are the main reservoir of <em>T. b. rhodesiense</em>.</p><p>During a blood meal, an infected tsetse fly injects trypomastigotes into the host skin tissue (<a class="graphic graphic_figure graphicRef85844" href="/z/d/graphic/85844.html" rel="external">figure 3</a>). A painful chancre (local inflammatory reaction) can develop at the site of inoculation. </p><p>The parasites enter regional lymphatics and then disseminate in the bloodstream, where the metacyclic trypomastigotes differentiate to long, slender forms that measure 15 to 35 microns. These can be seen on blood smear examination (<a class="graphic graphic_picture graphicRef85845" href="/z/d/graphic/85845.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef86899" href="/z/d/graphic/86899.html" rel="external">picture 2</a>) and are characterized by a flagellum and a kinetoplast (an organelle associated with the mitochondrion containing extranuclear DNA). Trypomastigotes can pass through the walls of blood and lymphatic vessels into connective tissues and thereby enter the cerebrospinal fluid and the brain. The skin may serve as a reservoir for trypanosomes [<a href="#rid22">22,23</a>]. </p><p>When ingested by a tsetse fly during a blood meal, trypomastigotes move to the midgut, transform into procyclic trypomastigotes (with different developmental, morphologic, and metabolic characteristics) and undergo replication. They migrate to the salivary gland, where they develop into epimastigotes, and finally, about three weeks after initial infection of the fly, develop into new metacyclic trypomastigotes ready to be transmitted to another host.</p><p class="headingAnchor" id="H3148692433"><span class="h2">Transmission</span><span class="headingEndMark"> — </span>HAT is transmitted to humans via the bite of a tsetse fly (<em>Glossina</em> spp). Tsetse flies tend to be found in warm, shaded areas and have an average lifespan of one to six months. Once trypanosomes have colonized the salivary glands, the fly remains infective for life. Flies are attracted by large moving objects and are especially drawn to dark colors [<a href="#rid24">24</a>]. Tsetse flies are restricted to the African continent where they occur in 31 species and subspecies, though not all tsetse flies play a role in the transmission of sleeping sickness. <em>T. b. gambiense</em> is transmitted via tsetse flies mainly of the <em>Glossina palpalis</em> group, and <em>T. b. rhodesiense</em> is transmitted via tsetse flies mainly of the <em>Glossina morsitans</em> group. These flies are found in tropical Africa between 14° north and 19° south of the equator, which defines the geographic range for transmission of HAT. </p><p>The <em>G. palpalis</em> vector requires humidity as encountered in dense riverine habitats, plantations, and mangroves in West and Central Africa. Humans are exposed to bites during daily activities including fishing, bathing, washing in small rivers or pools of water in rural areas, or while working in coffee or cocoa plantations.</p><p>The <em>G. morsitans</em> vector lives in drier and more open areas of woodlands and savannas in East and Southern Africa. These flies mainly feed on wild animals such as antelope (bushbucks) or on domestic animals such as cattle and goats. They do not bite humans frequently, but individuals who enter woodland areas and thickets where flies breed (such as farmers, honey gatherers, firewood collectors, hunters, poachers, fishermen, game wardens, and tourists to national parks and game reserves) are at risk of incidental infection. </p><p>Other means of transmission are considered to be rare; these include transmission via blood transfusion (theoretical), laboratory inoculation, and congenital infection [<a href="#rid25">25</a>]. The risk of congenital infection is unknown, but is regarded to be more common than recognized [<a href="#rid25">25,26</a>]. Urban and peri-urban transmission events are rare but have been described in Libreville (Gabon) and Kinshasa (the Democratic Republic of Congo) [<a href="#rid27">27</a>].</p><p>It has been proposed that individuals with asymptomatic infection may carry skin-dwelling trypanosomes and act as parasite reservoirs [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H3294543796"><span class="h2">Elimination</span><span class="headingEndMark"> — </span>The WHO targeted HAT for elimination as a public health problem by the year 2020 (defined as &lt;2000 reported cases per year and 90 percent reduction in at-risk areas reporting ≥1 case per 10,000 people annually) [<a href="#rid6">6,29</a>]. Additional 2030 targets include elimination of gambiense HAT transmission (resulting in zero cases reported) and elimination of rhodesiense HAT as a public health problem (no area reporting ≥1 case per 10,000 people annually) [<a href="#rid7">7</a>]. The goal for rhodesiense HAT is more complex due to its predominance in animal reservoirs.</p><p class="headingAnchor" id="H2215002735"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>During the lifecycle of <em>T. brucei</em>, there is modulation of the exposed surface antigens of the parasite. Metacyclic trypanosomes in the tsetse fly and bloodstream forms in mammalian and human hosts have proteins on their surface known as variant surface glycoprotein (VSG), which are highly immunogenic. Each trypanosome is covered with approximately 10 million copies of a single VSG [<a href="#rid30">30</a>].</p><p class="headingAnchor" id="H3512085614"><span class="h2">Innate immunity</span><span class="headingEndMark"> — </span>Innate immunity against <em>T. brucei</em> and other animal trypanosomes is due to the trypanolytic activity of apolipoprotein L-I (APOL1), which is bound to high-density lipoproteins in human serum [<a href="#rid31">31</a>]. This protein is taken up in the parasite by endocytosis and triggers osmotic swelling of the lysosomal compartment with subsequent cell death [<a href="#rid32">32</a>]. The importance of the APOL1 protein in innate immunity has been demonstrated by permissiveness of human infections when parasites otherwise not infective to humans (see above) have acquired resistance to APOL1 [<a href="#rid31">31</a>] or conversely when susceptible patients have mutations in the <em>APOL1</em> gene [<a href="#rid33">33</a>]. However, both <em>T. b. rhodesiense</em> and <em>T. b. gambiense</em> resist APOL1-mediated lysis [<a href="#rid34">34</a>]. <em>T. b. rhodesiense</em> expresses the serum resistance-associated protein, which binds to APOL1 and thereby inactivates its trypanolytic activity. <em>T. b. gambiense</em> resists through a combination of mechanisms, including reduced APOL1 uptake, faster APOL1 degradation, and membrane stiffening mediated by the <em>T. b. gambiense</em>-specific glycoprotein. Other innate immune mechanisms (eg, polymorphisms of genes encoding tumor necrosis factor or interleukins 6 and 10) may modulate the risk of latency in <em>T. b. gambiense</em> infections [<a href="#rid21">21</a>]. The G2 variant of <em>APOL1</em> gene is a risk factor for renal disease in African Americans but it may confer a degree of protection against <em>T. b. rhodesiense </em>infections [<a href="#rid35">35</a>]. </p><p class="headingAnchor" id="H461691595"><span class="h2">Evasion of host defense</span><span class="headingEndMark"> — </span><em>T. brucei</em> parasites can evade destruction by the mammalian host humoral immune response in the bloodstream by periodically switching their VSG, a phenomenon known as antigenic variation [<a href="#rid36">36,37</a>]. This results in characteristic waves of parasitemia during HAT infection. Trypanosomes express a different VSG during each successive wave of parasitemia and change their surface VSG each time the host begins to mount an effective immune response. In this way, the parasite is able to stay one step ahead of the host's antibody response [<a href="#rid38">38</a>]. </p><p class="headingAnchor" id="H2486965160"><span class="h2">Immune response</span><span class="headingEndMark"> — </span>Antigenic variation leads to nonspecific polyclonal B cell activation during infection and immunoglobulin (Ig)M is produced in large quantities. This can induce false positivity in antibody-based tests used to diagnose other infections [<a href="#rid16">16</a>]. Immune complexes form and secondary hyperplasia of the reticuloendothelial system occurs, particularly involving the spleen and lymph nodes. This process may lead to downregulation of the immune system. Therefore, generalized suppression of humoral and cellular immune responses may be seen in advanced stages of the disease [<a href="#rid39">39</a>].</p><p>The relative contribution of immune complex deposition, inflammatory infiltrates, vascular infiltration, and direct parasite invasion to organ damage in HAT is uncertain; it is likely that the pathogenesis of HAT reflects a complex combination of these mechanisms [<a href="#rid40">40</a>].</p><p class="headingAnchor" id="H2333420"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The clinical presentation of HAT is dependent on the parasite subspecies, the disease stage, and host factors. In general, the clinical manifestations of gambiense and rhodesiense HAT differ with respect to their frequency, severity, and progression (<a class="graphic graphic_table graphicRef129081" href="/z/d/graphic/129081.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H2969922244"><span class="h2">Disease stages</span><span class="headingEndMark"> — </span>The incubation period of rhodesiense HAT is less than three weeks. The incubation period of gambiense HAT is variable, with a range of weeks or months prior to onset of systemic symptoms [<a href="#rid41">41</a>]. </p><p>There are two stages of infection: the first stage, in which trypanosomes penetrate the skin and circulate in the blood and lymphatics, and the second stage, in which there is central nervous system (CNS) involvement. There is overlap in the clinical manifestations of the two stages and distinguishing between them on clinical grounds is usually not possible; lumbar puncture may be required to guide treatment. (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a>.)</p><p>Gambiense HAT is usually slowly progressive, with an oligosymptomatic phase that may last months or years. Patients usually present indolently with fever, neurologic manifestations, weight loss, and lymphadenopathy. The estimated average duration of first stage is 526 days (95% CI 357-833) and the estimated average duration of second stage is 252 days (95% CI 171-399) [<a href="#rid42">42,43</a>]. </p><p>Rhodesiense HAT is usually rapidly progressive within weeks. Patients often present fulminantly with a severe acute febrile illness, often with signs of hemodynamic instability. Patients may be critically ill, with multiorgan involvement, thrombocytopenia, and disseminated intravascular coagulopathy leading to bleeding [<a href="#rid44">44</a>]. </p><p class="headingAnchor" id="H2334707"><span class="h3">First stage: Hemo-lymphatic disease</span><span class="headingEndMark"> — </span>First-stage HAT consists of no CNS involvement, defined by cerebrospinal fluid (CSF) white blood cell (WBC) count ≤5 cells/microL and no trypanosomes in the CSF. (See <a class="local">'Cerebrospinal fluid'</a> below.)</p><p>The first sign of HAT infection may be the trypanosomal chancre; when present, it typically appears approximately after one week at the site of the tsetse bite. A typical chancre has a marked and painful erythema, about 2 to 5 cm in diameter, which later becomes indurated, with a considerable variation in appearance (<a class="graphic graphic_picture graphicRef130332" href="/z/d/graphic/130332.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef86882" href="/z/d/graphic/86882.html" rel="external">picture 4</a>) [<a href="#rid44">44</a>]. The chancre can ulcerate, with later peripheral desquamation and hyperpigmentation, and usually resolves spontaneously after several weeks. Chancres are observed more frequently in travelers (rhodesiense HAT 88 percent; gambiense HAT 56 percent) than residents of endemic areas (rhodesiense HAT 5 to 26 percent; gambiense HAT &lt;5 percent) (<a class="graphic graphic_table graphicRef129081" href="/z/d/graphic/129081.html" rel="external">table 2</a>) [<a href="#rid26">26,45</a>].</p><p>Following skin penetration, trypanosomes travel to regional lymphatics, where they proliferate and cause lymphadenitis. In <em>T. b. gambiense</em> infection, lymphadenopathy typically occurs in the posterior cervical nodes but can develop at any site. Painless enlargement of the soft, mobile posterior cervical nodes is classically referred to as "Winterbottom's sign" (<a class="graphic graphic_picture graphicRef129083" href="/z/d/graphic/129083.html" rel="external">picture 5</a>). This finding is easily overlooked. In <em>T. b. rhodesiense</em> infection, lymphadenopathy occurs less frequently. When present, it occurs more commonly in the submandibular, axillary, or inguinal regions than in the cervical region [<a href="#rid46">46</a>].</p><p>Early symptoms of HAT infection include intermittent fever, headache, malaise, and musculoskeletal pain; these symptoms may correspond with successive waves of parasitemia and antibody production. The pattern of fever is irregular and remittent, although such patterns tend not to be diagnostically useful. Fever is more pronounced in the first stage than in the second stage [<a href="#rid47">47</a>]. Hepatomegaly and particularly splenomegaly may be observed, and generalized lymphadenopathy may be present. </p><p>Neurologic or psychiatric symptoms (such as headache, behavioral change, sleeping disorder) may be observed. Other nonspecific symptoms may be present including pruritus, weight loss, gastrointestinal symptoms (such as nausea, vomiting, abdominal pain, diarrhea), and facial swelling [<a href="#rid26">26</a>]. Neuroendocrine disturbances (leading to amenorrhea in women or impotence in men) may also occur. </p><p>Cardiac involvement can be observed by electrocardiographic alterations in gambiense HAT; rarely, cardiomyopathy causes severe congestive heart failure [<a href="#rid48">48</a>]. In rhodesiense HAT, myocarditis or pancarditis is more severe and can be fatal in some cases [<a href="#rid49">49,50</a>]. </p><p class="headingAnchor" id="H2333441"><span class="h3">Second stage: Meningo-encephalitis</span><span class="headingEndMark"> — </span>Second-stage HAT consists of systemic HAT with CNS involvement, defined by CSF WBC count &gt;5 cells/microL with or without trypanosomes in the CSF. (See <a class="local">'Cerebrospinal fluid'</a> below.)</p><p>For gambiense HAT, an additional sub-category, severe second-stage disease, was established in the World Health Organization 2019 guidelines; this is defined as ≥100 WBC/microL in CSF (with or without trypanosomes in CSF) [<a href="#rid1">1</a>]. Such staging is important for guiding management, since <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">fexinidazole</a> is less efficacious in patients with CSF WBC ≥100 cells/microL. Clinical manifestations consistent with severe second-stage HAT are summarized in the table (<a class="graphic graphic_table graphicRef122839" href="/z/d/graphic/122839.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a>.)</p><p>CNS symptoms include headache, difficulty in concentrating, difficulty completing complex operations (2- or 3-stage tasks), personality changes, psychosis, sensory disorders, tremor, and ataxia [<a href="#rid26">26</a>]. Sleep disorder is one of the most striking characteristics of second-stage HAT; for this reason the disease is also called "sleeping sickness." Alteration of the circadian sleep/wake cycle leads to daytime somnolence, which may already be prominent in the first stage. Meningismus and focal neurologic signs may occur but are unusual. The patient gradually deteriorates to a stuporous or comatose state. Convulsions may occur. Cachexia, wasting, and malnutrition develop as patients are too drowsy to eat. Patients are at risk for complications such as aspiration pneumonia and other secondary bacterial infections. </p><p>In one series including more than 2500 patients with second-stage gambiense HAT, the following symptoms and signs were most frequent [<a href="#rid47">47</a>]: headache (79 percent), sleep disorder (74 percent), lymphadenopathy (56 percent), pruritus (51 percent), motor weakness (35 percent), malnutrition (25 percent), unusual behavior (25 percent), disturbed appetite (23 percent), walking difficulties (22 percent), tremor (21 percent), fever (16 percent), speech disorder (13 percent), and abnormal movements (11 percent).</p><p>Most of the neuropsychiatric signs and symptoms can be treated successfully; however, depending on the severity of the disease at the time of therapy, irreversible sequelae may occur [<a href="#rid26">26</a>]. In the absence of treatment, second-stage HAT is fatal [<a href="#rid51">51</a>].</p><p>Neurologic or psychiatric signs may be also mild or absent at the time of diagnosis [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H727878949"><span class="h3">Relapse</span><span class="headingEndMark"> — </span>Relapse may occur up to 24 months after completion of treatment. For patients who present &gt;24 months after completion of treatment with diagnostic evidence of trypanosomiasis, this is usually interpreted as reinfection. (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention", section on 'Approach to relapse'</a>.)</p><p class="headingAnchor" id="H2333470"><span class="h2">Travelers from non-endemic areas</span><span class="headingEndMark"> — </span>Clinical features among returning travelers may differ from clinical features among individuals in endemic settings (<a class="graphic graphic_table graphicRef129081" href="/z/d/graphic/129081.html" rel="external">table 2</a>) and misdiagnosis outside endemic areas is common [<a href="#rid15">15,44,45</a>]. Among travelers, rhodesiense HAT is observed more frequently than gambiense HAT, mainly after visits to game parks (see <a class="local">'Epidemiology'</a> above). In rhodesiense HAT, timely diagnosis is critical given rapid disease progression.</p><p>A history of a painful tsetse fly bite may be reported [<a href="#rid44">44</a>]. In both forms of HAT, patients typically present acutely with fever [<a href="#rid45">45</a>]. For rhodesiense HAT, the incubation period is less than three weeks and may be as short as a few days. For gambiense HAT, the incubation period is frequently less than one month [<a href="#rid53">53</a>], whereas for individuals living in nonendemic countries, late presentations after several years may occur [<a href="#rid15">15,25</a>].</p><p>Dermatologic manifestations include: </p><p class="bulletIndent1"><span class="glyph">●</span>Trypanosomal chancre − A trypanosomal chancre is a key finding that may be overlooked or misinterpreted (<a class="graphic graphic_picture graphicRef130332" href="/z/d/graphic/130332.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef86882" href="/z/d/graphic/86882.html" rel="external">picture 4</a>) [<a href="#rid44">44,45</a>]. Chancres are observed more frequently in travelers (rhodesiense HAT 88 percent; gambiense HAT 56 percent) than in residents of endemic areas (rhodesiense HAT 5 to 26 percent; gambiense HAT &lt;5 percent) [<a href="#rid26">26,45</a>]. (See <a class="local">'First stage: Hemo-lymphatic disease'</a> above.)</p><p></p><p class="bulletIndent1">Chancre aspiration may be diagnostic. (See <a class="local">'Tissue aspirate'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Trypanosomal rash − Following the initial episode of fever, a trypanosomal rash develops in approximately one-third of travelers; it is characterized by nonpruritic, blotchy, irregular, erythematous macules mainly on the trunk. Frequently, the rash develops a central area with normal colored skin, with a circinate or serpiginous appearing outline (<a class="graphic graphic_picture graphicRef50285" href="/z/d/graphic/50285.html" rel="external">picture 6</a>). The rash is evanescent and reappears in other locations over a period of several weeks [<a href="#rid25">25,45,53</a>]. </p><p></p><p>In travelers, these dermatologic manifestations may be observed in first-stage and/or second-stage disease. </p><p>In patients with severe disease due to rhodesiense HAT, clinical features may include hemodynamic instability, disseminated intravascular coagulopathy, multiorgan failure, and myocarditis [<a href="#rid44">44</a>]. </p><p>Among travelers, sleep disorders and neuropsychiatric signs are observed less frequently, as patients are more likely to be diagnosed and treated during the first stage [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H233444980"><span class="h2">Patients with HIV infection</span><span class="headingEndMark"> — </span>Thus far, it is uncertain whether the natural history of HAT is influenced by HIV infection, and it is uncertain whether patients with HIV infection may be at increased risk for treatment failure [<a href="#rid54">54</a>]. </p><p class="headingAnchor" id="H2116707167"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>A number of nonspecific laboratory findings may be associated with HAT. Anemia is common (present in more than half of patients) and may be due in part to immune-mediated hemolysis [<a href="#rid45">45</a>] and cytokine-related bone marrow depression [<a href="#rid55">55</a>]. Leukocytosis and thrombocytopenia may be present, possibly related to splenic sequestration and massive cytokine release. Hypergammaglobulinemia, largely related to raised levels of polyclonal IgM, is also characteristic and can give rise to false-positive results on serologic tests for other diseases. Hypoalbuminemia, hypocomplementemia, elevated erythrocyte sedimentation rate, and elevated C-reactive protein are frequently observed.</p><p class="headingAnchor" id="H2"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H2358528"><span class="h2">Clinical approach</span><span class="headingEndMark"> — </span>A definitive diagnosis of HAT requires demonstration of trypanosomes in body fluids (blood and/or cerebrospinal fluid [CSF]) or tissues (lymph node or chancre aspirate) via microscopy [<a href="#rid56">56</a>]. </p><p class="headingAnchor" id="H1546558485"><span class="h3">Gambiense HAT</span><span class="headingEndMark"> — </span>In endemic areas, the diagnosis of gambiense HAT should be suspected in individuals with epidemiologic exposure (residence in an endemic area (<a class="graphic graphic_figure graphicRef129080" href="/z/d/graphic/129080.html" rel="external">figure 1</a>)). In these areas, HAT is most frequently diagnosed in the context of screening; patients may or may not be symptomatic. </p><p>Outside endemic areas, the diagnosis of gambiense HAT should be suspected in individuals with epidemiologic exposure (travel to an endemic area (<a class="graphic graphic_figure graphicRef129080" href="/z/d/graphic/129080.html" rel="external">figure 1</a>)) in the setting of relevant signs or symptoms (early symptoms of fever, trypanosomal chancre or rash, headache, arthralgia, and lymphadenopathy; later symptoms of neurologic manifestations). A high degree of clinical suspicion is necessary for a timely diagnosis.</p><p>Diagnostic evaluation begins with serologic assessment using a rapid diagnostic test; these include the card agglutination test for trypanosomiasis (CATT) or rapid lateral flow tests (<a class="graphic graphic_algorithm graphicRef130705" href="/z/d/graphic/130705.html" rel="external">algorithm 1</a>) (see <a class="local">'Serologic tests'</a> below). Patients with a positive serologic test should undergo confirmatory testing. Those with lymphadenopathy warrant lymph node aspiration with examination for parasites. If there is no lymphadenopathy, or the lymph node aspirate does not demonstrate trypanosomes, patients should undergo blood examination using a concentration technique; tools include microhematocrit centrifugation technique (mHCT) and mini anion-exchange centrifugation technique (mAECT). Indications for CSF examination depend on findings of initial diagnostic evaluation, clinical manifestations, and the available treatment options. (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a>.) </p><p class="headingAnchor" id="H117421036"><span class="h3">Rhodesiense HAT</span><span class="headingEndMark"> — </span>The diagnosis of rhodesiense HAT should be suspected in individuals with epidemiologic exposure (travel to or residence in an endemic area (<a class="graphic graphic_figure graphicRef129080" href="/z/d/graphic/129080.html" rel="external">figure 1</a>)), in the setting of relevant signs or symptoms (early symptoms of fever, trypanosomal chancre or rash, headache, arthralgia, lymphadenopathy; later symptoms of neurologic manifestations). </p><p>The diagnosis of rhodesiense HAT can often be made via blood smear or chancre fluid; additional blood examination may be helpful in some cases (<a class="graphic graphic_algorithm graphicRef130501" href="/z/d/graphic/130501.html" rel="external">algorithm 2</a>). </p><p class="headingAnchor" id="H4009539369"><span class="h2">Diagnostic tools</span></p><p class="headingAnchor" id="H2112928766"><span class="h3">Serologic tests</span></p><p class="headingAnchor" id="H2677450240"><span class="h4">Gambiense HAT</span><span class="headingEndMark"> — </span>Serologic screening is the starting point for diagnosis of gambiense HAT (<a class="graphic graphic_algorithm graphicRef130705" href="/z/d/graphic/130705.html" rel="external">algorithm 1</a>). Serologic tests may be used for surveillance among asymptomatic individuals as well as the clinical evaluation of symptomatic patients.</p><p>Rapid diagnostic tests (RDTs) for diagnosis of gambiense HAT include the CATT and rapid lateral flow tests for detection of antibodies against purified variant surface glycoproteins: </p><p class="bulletIndent1"><span class="glyph">●</span>CATT is based upon agglutination of freeze-dried trypanosomes in the presence of a variant-specific antibody in blood, plasma, or serum. It is well suited for HAT surveillance in populations at risk [<a href="#rid57">57</a>]. The sensitivity is generally 94 to 98 percent; the specificity depends in part upon whether whole blood (97 percent specificity) or plasma/serum dilutions are used (further increasing specificity) [<a href="#rid58">58</a>]. The specificity may be reduced by cross-reactivity with antibodies against nonpathogenic animal trypanosomes. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid lateral flow tests detect antibodies against native variant surface glycoproteins [<a href="#rid59">59,60</a>] or against a combination of recombinant invariant and variant surface glycoproteins [<a href="#rid61">61</a>]. These tests are generally used for initial screening of symptomatic patients; they are well suited for individual diagnosis of HAT. In general, their sensitivity is 90 to 100 percent (with some reports of lower sensitivity [<a href="#rid61">61</a>]). Test specificity of available rapid tests is lower than of CATT, and their specificity is usually ≥85 percent [<a href="#rid59">59,60,62-64</a>].</p><p></p><p>Serologic tests that require laboratory facilities include enzyme-linked immunosorbent assay (ELISA) and inhibition ELISA [<a href="#rid65">65</a>], indirect fluorescent antibody test (IFAT), and the trypanolysis test [<a href="#rid66">66</a>]. The sensitivity and specificity for IFAT varies depending on the antigen used (75 to 95 percent and &gt;95 percent, respectively) [<a href="#rid67">67-69</a>]. The sensitivity and specificity of ELISA and inhibition ELISA are 95 to 100 percent and 97 to 100 percent, respectively [<a href="#rid65">65,70-73</a>]. The sensitivity and specificity for the trypanolysis test are 95 percent and 100 percent, respectively [<a href="#rid59">59,66</a>].</p><p>Additional information on use of these tools for surveillance is presented separately. (See  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention", section on 'Surveillance'</a>.) </p><p class="headingAnchor" id="H4209573084"><span class="h4">Rhodesiense HAT</span><span class="headingEndMark"> — </span>For diagnosis of rhodesiense HAT, no rapid tests are available. Serologic tests that require laboratory facilities include ELISA [<a href="#rid74">74,75</a>] or IFAT using whole parasites or crude trypanosome extracts [<a href="#rid76">76-78</a>] (<a class="graphic graphic_algorithm graphicRef130501" href="/z/d/graphic/130501.html" rel="external">algorithm 2</a>). The sensitivity (71 to 92 percent) and specificity of such tests rhodesiense HAT are generally lower than those reported for gambiense HAT, given the acuity of illness due to rhodesiense HAT and the use of crude extracts for antibody detection.</p><p class="headingAnchor" id="H3620474336"><span class="h3">Parasite detection</span><span class="headingEndMark"> — </span>Trypanosomes may be visualized in tissue (lymph node or chancre aspirate) or body fluids (blood or cerebrospinal fluid). The morphologic appearances of <em>T. b. rhodesiense</em> and <em>T. b. gambiense</em> are identical; in general, the infections are differentiated based on geographic exposure. </p><p class="headingAnchor" id="H2683464900"><span class="h4">Tissue aspirate</span><span class="headingEndMark"> — </span>A lymph node aspirate is a traditional diagnostic and screening tool for gambiense HAT, which is more commonly associated with lymphadenopathy than rhodesiense HAT. If enlarged cervical lymph nodes are present, we favor pursuing aspiration (<a class="graphic graphic_picture graphicRef129083" href="/z/d/graphic/129083.html" rel="external">picture 5</a>); the technique is relatively simple and may be diagnostic even if blood examination is unrevealing. </p><p>The lymph node aspirate may demonstrate motile parasites on direct microscopy of a wet mount with ground-glass illumination; trypanosomes may also be seen after fixation and staining with Giemsa. The sensitivity of this technique is variable (19 to 77 percent) but highest during early infection [<a href="#rid79">79-82</a>]. </p><p>For patients with a trypanosomal chancre (more common among travelers than among individuals in endemic areas), chancre aspirate may demonstrate trypanosomes before they are detectable in blood; either wet preparation or fixation and staining may be performed.</p><p class="headingAnchor" id="H3704423569"><span class="h4">Blood examination</span></p><p class="headingAnchor" id="H2450957028"><span class="h5">Direct smear</span><span class="headingEndMark"> — </span>Trypanosomes may be visualized on direct thin blood smear preparations or on Giemsa-stained thin or thick smears (<a class="graphic graphic_picture graphicRef85845" href="/z/d/graphic/85845.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef86899" href="/z/d/graphic/86899.html" rel="external">picture 2</a>). However, the sensitivity of a smear is much lower than that of a concentrated specimen. </p><p>For diagnosis of gambiense HAT, a smear should be performed only if concentration techniques are not available. The sensitivity of thick smears is 27 to 35 percent; the sensitivity of thin smears is 4 to 22 percent [<a href="#rid79">79,80</a>]. This is because gambiense HAT is generally associated with a lower level of parasitemia (often below the detection limit of 5000 parasites/mL for thick smears). Specimen concentration may be used to increase the likelihood of diagnosis. (See <a class="local">'Concentrated specimens'</a> below.)</p><p>For diagnosis of rhodesiense HAT, trypanosomes are usually readily detected in stained thin or thick films or wet preparations of blood [<a href="#rid44">44</a>]. The sensitivity of smears for diagnosis of rhodesiense HAT is not well studied. In the setting of persistent symptoms but absence of trypanosomes on serial blood smears, clinical suspicion for rhodesiense HAT should be diminished and alternative diagnoses should to be considered.</p><p>Some cases of smear-negative, culture-positive HAT have been observed [<a href="#rid83">83</a>]; however, culture of trypanosomes in liquid culture medium remains a research tool. </p><p>There is no role for serial smears to monitor for clearance of parasitemia.</p><p class="headingAnchor" id="H2748296436"><span class="h5">Concentrated specimens</span><span class="headingEndMark"> — </span>The sensitivity of microscopy may be improved by concentrating the specimen. This approach is most useful for diagnosis of gambiense HAT (given relatively low parasitemia with this species) and in the context of elimination programs in endemic areas [<a href="#rid84">84-86</a>]. Concentration techniques are rarely used for diagnosis of rhodesiense HAT since direct smear is usually sufficient for diagnosis. (See <a class="local">'Direct smear'</a> above.)</p><p>Tools for concentration include anion exchange centrifugation, hematocrit centrifugation, and buffy coat separation:</p><p class="bulletIndent1"><span class="glyph">●</span>Mini anion-exchange centrifugation technique (mAECT) −<strong> </strong>mAECT is a method for separation of red blood cells and trypanosomes; the charge difference around a pH of 8 allows chromatographic separation on diethylaminoethyl cellulose [<a href="#rid87">87,88</a>]. The technique is demonstrated in an online <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fvimeo.com%2F125146540&amp;token=87FGOx%2BvCnvlJw8luenyfVlENGQTzQc2iA2TE7uVcE0Tr4kC%2BwAyRk318qE1kpcf&amp;TOPIC_ID=5697" target="_blank">video</a>. Blood for mAECT should be collected in heparin; the charge of other anticoagulants may inhibit binding of red blood cells to the cellulose. </p><p></p><p class="bulletIndent1">The sensitivity of mAECT for diagnosis of gambiense HAT is 75 to 85 percent and may reach more than 90 percent by applying the buffy coat obtained after centrifuging ≤10 mLs of blood [<a href="#rid79">79-82</a>]. Ready-to-use mAECT columns are produced in the Democratic Republic of Congo and Côte d’Ivoire for use in endemic areas; outside these areas, mAECT is performed only in specialized laboratories. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microhematocrit centrifugation technique (mHCT) − To perform mHCT, blood is centrifuged in capillary tubes for 5 minutes at 12,000 rpm, resulting in separation of the red blood cells from white blood cells and trypanosomes. The buffy coat layer consists of white blood cells; trypanosomes are localized within or on top of this layer. The trypanosomes may be recognized under the microscope by their characteristic movement. When performed by an experienced microscopist, the sensitivity of this technique for diagnosis of gambiense HAT is approximately 50 percent [<a href="#rid79">79,80,82</a>]. The cost of this technique is relatively low and it is commonly used in <em>T. b. gambiense</em> endemic areas.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Quantitative buffy coat technique − The quantitative buffy coat technique is a variation of the mHCT. It utilizes acridine orange in the capillary tube, which binds to the trypanosomes kinetoplast and nucleus, resulting in improved parasite visualization [<a href="#rid84">84</a>]. This technique is rarely used in endemic areas due to cost. </p><p></p><p class="headingAnchor" id="H6"><span class="h4">Cerebrospinal fluid</span><span class="headingEndMark"> — </span>For patients with established HAT, CSF examination may be needed to guide the management approach (<a class="graphic graphic_algorithm graphicRef130497" href="/z/d/graphic/130497.html" rel="external">algorithm 3</a>) (see  <a class="medical medical_review" href="/z/d/html/5688.html" rel="external">"Human African trypanosomiasis: Treatment and prevention"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>For gambiense HAT in settings where <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">fexinidazole</a> is available, CSF examination is warranted for patients with symptoms and signs consistent with severe second-stage disease (<a class="graphic graphic_table graphicRef122839" href="/z/d/graphic/122839.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. CSF examination is also warranted for all patients &lt;6 years or &lt;20 kg. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For gambiense HAT in settings where <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">fexinidazole</a> is not available, CSF examination is warranted to differentiate between first-stage (defined by ≤5 white blood cell (WBC)/microL of CSF and no trypanosomes in CSF) and second-stage disease (&gt;5 WBC/microL of CSF or trypanosomes in CSF).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For rhodesiense HAT, CSF examination is needed to differentiate between first-stage (≤5 WBC/microL of CSF and no trypanosomes in CSF) and second-stage disease (&gt;5 WBC/microL of CSF or trypanosomes in CSF).</p><p></p><p class="bulletIndent1">Given that trypanosomes are commonly detected on blood smear in the setting of rhodesiense HAT, a dose of <a class="drug drug_general" data-topicid="10291" href="/z/d/drug information/10291.html" rel="external">suramin</a> is often administered prior to lumbar puncture to reduce parasitemia and minimize the theoretic risk of iatrogenic introduction of trypanosomes into the CSF (in case of a traumatic lumbar puncture) [<a href="#rid89">89</a>]. </p><p></p><p>Trypanosomes are generally scanty in CSF but may be observed on direct examination or following concentration by centrifugation [<a href="#rid90">90</a>]. In gambiense HAT, the sensitivity of direct trypanosome detection in CSF (by observation in the cell counting chamber or on smears) is around 10 percent; this is a reflection of the relatively low parasitemia observed for this species [<a href="#rid79">79</a>]. Following CSF centrifugation, a diagnostic sensitivity of 18 to 79 percent has been observed [<a href="#rid82">82,90</a>]. </p><p>For patients with suspected gambiense HAT (based on the combination of epidemiologic exposure, clinical manifestations, serologic screening, and other diagnostic test results if available, but unremarkable lymph node aspirate and concentrated blood specimen), CSF examination may be used to detect trypanosomes and establish a definitive diagnosis of HAT. While the sensitivity of CSF examination may appear low, CSF centrifugation followed by visualization of CSF trypanosomes has facilitated diagnosis of gambiense HAT in patients with negative blood examinations in a small number of cases (4 to 8 percent) [<a href="#rid79">79,82</a>].</p><p>Second-stage HAT is usually associated with CSF WBC counts below 200 cells/microL (typically lymphocyte predominant, with occasional eosinophils); however, levels as high as 2000 cells/microL may be observed. A correlation between CSF WBC (especially ≥100 WBC/microL) and occurrence of neurologic signs and symptoms has been described [<a href="#rid47">47</a>]. </p><p>There is often a moderate elevation in protein concentration (overall range approximately 350 mg/L up to 2000 mg/L) [<a href="#rid91">91,92</a>], which may be observed in first-stage or second-stage HAT [<a href="#rid93">93</a>]. Glucose is typically normal or only modestly decreased. Elevated intracranial pressure may develop. </p><p>Intrathecal synthesis of IgM in second stage results in a characteristic 40-fold increase in CSF IgM (up to 300 mg/L), and three- to fourfold elevations in IgG and IgA [<a href="#rid93">93</a>]. A characteristic CSF finding associated with second-stage HAT is the presence of Mott cells (<a class="graphic graphic_picture graphicRef129085" href="/z/d/graphic/129085.html" rel="external">picture 7</a>); these are large activated plasma cells with IgM-containing eosinophilic inclusions [<a href="#rid92">92,94,95</a>]. The CSF lactate concentration is normal to slightly increased (&lt;3.5 mmol/L). </p><p>Neopterin, a marker for cellular immune activation, is largely a research tool and intrathecal inflammation in second-stage gambiense HAT may be accompanied by a rise in neopterin (&gt;14.3 nmol/L) [<a href="#rid56">56,92,96,97</a>]. </p><p class="headingAnchor" id="H1141687788"><span class="h3">Additional tools outside endemic areas</span><span class="headingEndMark"> — </span>Additional tools outside endemic areas include radiographic imaging, electroencephalogram (EEG), and molecular tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Data on magnetic resonance imaging (MRI) findings of HAT are limited [<a href="#rid98">98-100</a>]. In some cases, T2-weighted MRI scans show hyperintense signals in frontal cortical and periventricular white matter, together with involvement of basal ganglia and cerebellum [<a href="#rid98">98</a>]. Another report noted multiple lesions in white and central gray matter and cortex [<a href="#rid99">99</a>]. Resolution of radiographic abnormalities may take many months or longer. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with neurologic involvement often have abnormal EEGs, usually demonstrating slow wave oscillations (delta waves) [<a href="#rid40">40</a>]. However, this is a nonspecific finding [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Molecular techniques for HAT diagnosis include polymerase chain reaction and loop-mediated isothermal amplification. The sensitivity and specificity of these tests in research laboratories is around 90 percent [<a href="#rid101">101-104</a>]; their diagnostic performance in the context of a clinical laboratory requires further evaluation [<a href="#rid105">105</a>]. Newly emerging and promising molecular tools include reverse transcriptase quantitative polymerase chain reaction, multiplexing, and specific high-sensitivity enzymatic reporter unlocking [<a href="#rid106">106-108</a>]. These molecular tools are rarely used in most endemic settings; they are costly, time consuming, and require specialized equipment and personnel. In settings where available, it may be used to complement serologic or parasitologic diagnosis to increase suspicion for HAT [<a href="#rid109">109</a>]. </p><p></p><p class="headingAnchor" id="H2359067"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of HAT includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Bacterial meningitis – Meningitis is characterized by acute onset of fever, nausea, vomiting, headache, confusion, and myalgia. In meningococcal infection, nonblanching purpuric rash may be observed. The infection is transmitted by person-to-person contact and occurs worldwide; the highest rate of meningococcal infection is in the meningitis belt of sub-Saharan Africa (from Senegal in the west to Ethiopia in the east). The incubation period is 2 to 10 days, and the diagnosis is established via culture of blood or spinal fluid, agglutination tests, or polymerase chain reaction. (See  <a class="medical medical_review" href="/z/d/html/1287.html" rel="external">"Clinical features and diagnosis of acute bacterial meningitis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Malaria – Malaria is characterized by fever, malaise, nausea, vomiting, abdominal pain, diarrhea, myalgia, and anemia. Cerebral malaria is an encephalopathy that presents with impaired consciousness, delirium, and/or seizures; focal neurologic signs are unusual. Malaria is transmitted by <em>Anopheles</em> mosquitoes. The incubation period of malaria due to <em>Plasmodium falciparum</em> is usually 7 to 30 days (but may be longer). The diagnosis of malaria is established by visualization of parasites on peripheral smear and/or rapid antigen tests. (See  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a> and  <a class="medical medical_review" href="/z/d/html/5707.html" rel="external">"Laboratory tools for diagnosis of malaria"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV infection – Acute HIV infection is commonly characterized by fever, lymphadenopathy, sore throat, rash, myalgia/arthralgia, and headache. The infection is transmitted sexually, and infection occurs worldwide. The incubation period is two to four weeks. The diagnosis is established via immunoassay and assessed using viral load. (See  <a class="medical medical_review" href="/z/d/html/86984.html" rel="external">"Acute and early HIV infection: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tuberculosis – Tuberculosis (TB) is characterized by cough &gt;2 to 3 weeks' duration, lymphadenopathy, fevers, night sweats, and weight loss. Manifestations of TB involving the central nervous system (CNS) include headache, malaise, and altered mental status; late manifestations include cranial nerve palsies, seizures, and coma. Transmission is human to human, and infection occurs worldwide. The incubation period is at least three months. Diagnostic evaluation begins with chest radiography, followed by sputum acid-fast bacilli smear and nucleic acid amplification testing. The diagnosis of CNS TB is established by spinal fluid examination. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/8009.html" rel="external">"Central nervous system tuberculosis: An overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cryptococcal meningitis – Cryptococcal meningitis often presents subacutely and may be associated with cranial neuropathies. Immunosuppression (due to HIV infection or other causes) is an important risk factor. The cerebrospinal fluid (CSF) profile classically demonstrates elevated opening pressure, low white blood cell count with a mononuclear predominance, slightly elevated protein concentration, and low glucose concentration. Definitive diagnosis is made by CSF culture; a positive cryptococcal antigen in the CSF or serum strongly suggests the presence of infection. (See  <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/2447.html" rel="external">"Clinical manifestations and diagnosis of Cryptococcus neoformans meningoencephalitis in patients without HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Toxoplasmosis – Cerebral toxoplasmosis is the most common CNS infection in patients with HIV/AIDS and CD4 &lt;100 cells/microL who are not receiving appropriate prophylaxis. Clinical manifestations include headache, altered mental status, fever, focal neurologic deficits, and seizures. Transmission is via ingestion of infectious oocysts or undercooked meat from an infected animal. The diagnosis is usually presumptive in the setting of CD4 &lt;100 cells/microL, positive <em>Toxoplasma gondii</em> serology, and ring-enhancing lesions on brain imaging. (See  <a class="medical medical_review" href="/z/d/html/3710.html" rel="external">"Toxoplasmosis in patients with HIV"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>CNS lymphoma – HIV-related primary CNS lymphoma is an AIDS-defining malignancy that is strongly related to Epstein-Barr virus infection and immunosuppression. Symptoms may include headache, blurred vision, motor difficulties, and personality changes. The diagnosis is established by biopsy. (See  <a class="medical medical_review" href="/z/d/html/4751.html" rel="external">"HIV-related lymphomas: Primary central nervous system lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurosyphilis – Forms of neurosyphilis include meningitis and meningovascular disease; infection may be asymptomatic in some cases. Symptomatic syphilitic meningitis is typically manifested by headache, confusion, nausea and vomiting, and stiff neck. Visual acuity may be impaired and/or cranial neuropathies may be present. Syphilitic meningitis can cause an infectious arteritis that may affect vessels in the subarachnoid space resulting in thrombosis, ischemia, and stroke. The diagnosis is established with serum treponemal testing and spinal fluid examination with CSF Venereal Disease Research Laboratory test. (See  <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">"Neurosyphilis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Enteric fever – Enteric fever refers to both typhoid fever (caused by <em>Salmonella enterica</em> serotype Typhi [formerly <em>S. typhi</em>]) and paratyphoid fever (caused by <em>S. enterica</em> serotype Paratyphi A, B, and C worldwide). Enteric fever is characterized by abdominal pain, fever, and chills. Classic manifestations include relative bradycardia, pulse-temperature dissociation, and "rose spots" (faint salmon-colored macules on the trunk and abdomen). Hepatosplenomegaly, intestinal bleeding, and perforation may occur, leading to secondary bacteremia and peritonitis. Patients with severe enteric fever may develop "typhoid encephalopathy," with altered consciousness, delirium, and confusion. Transmission is fecal-oral; the incubation period is 6 to 30 days. The diagnosis is established via culture of blood, stool, or other specimens. (See  <a class="medical medical_review" href="/z/d/html/2708.html" rel="external">"Enteric (typhoid and paratyphoid) fever: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Psychiatric illness – HAT may be misdiagnosed as psychiatric illness, especially in individuals living in nonendemic countries, when epidemiologic exposure is not recognized.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Viral hemorrhagic fever – Viral hemorrhagic fevers include Lassa, Ebola, Marburg, Crimean-Congo hemorrhagic fever, and yellow fever. In general patients present abrupt onset of nonspecific symptoms and signs, such as fever, malaise, headache, and myalgias. Vomiting and diarrhea may occur, often leading to significant fluid loss. Patients with worsening disease display hypotension and electrolyte imbalances leading to shock and multiorgan failure, sometimes accompanied by hemorrhage. These manifestations may occur in the setting of rhodesiense HAT. (See related topics). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other dermatologic conditions − A trypanosomal chancre may be misidentified as an insect or arachnid bite, bacterial cellulitis, or eschar. A trypanosomal chancre is not associated with necrosis and is usually larger than the eschar observed in the setting of African tick bite fever. (See  <a class="medical medical_review" href="/z/d/html/4088.html" rel="external">"Insect and other arthropod bites"</a> and  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7908.html" rel="external">"Other spotted fever group rickettsial infections", section on 'R. africae (African tick bite fever)'</a>.)</p><p></p><p class="headingAnchor" id="H4241093"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology – </strong>Human African trypanosomiasis (HAT), also known as sleeping sickness, is caused by protozoan parasites transmitted by tsetse flies. There are two forms of the disease: an acute form occurring mainly in East and Southern Africa and caused by <em>Trypanosoma brucei rhodesiense</em> (rhodesiense HAT) and a more chronic form occurring mainly in West and Central Africa caused by <em>Trypanosoma brucei gambiense</em> (gambiense HAT) (<a class="graphic graphic_table graphicRef85846" href="/z/d/graphic/85846.html" rel="external">table 1</a> and <a class="graphic graphic_figure graphicRef129080" href="/z/d/graphic/129080.html" rel="external">figure 1</a>). (See <a class="local">'Introduction'</a> above and <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Disease stages – </strong>The incubation period of gambiense HAT is variable, with a range of weeks or months; the disease is usually slowly progressive, with an oligosymptomatic phase that may last months or years. The incubation period of rhodesiense HAT is less than three weeks, and the disease is usually rapidly progressive within weeks. There are two stages of HAT infection. (See <a class="local">'Disease stages'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>First stage – </strong>In the first stage, trypanosomes penetrate the skin and circulate in the blood and lymphatics. The first sign of HAT infection may a chancre at the site of the tsetse bite. In gambiense infection, lymphadenopathy typically occurs in the posterior cervical nodes. In rhodesiense infection, lymphadenopathy occurs less frequently; when present, it occurs more commonly in the submandibular, axillary, or inguinal regions than in the cervical region. Additional early HAT symptoms include intermittent fever, headache, malaise, and musculoskeletal pain. (See <a class="local">'First stage: Hemo-lymphatic disease'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Second stage – </strong>The second stage consists of central nervous system involvement, defined by cerebrospinal fluid (CSF) white blood cell (WBC) count &gt;5 cells/microL. For gambiense HAT, an additional subcategory, severe second-stage disease, was established in the World Health Organization 2019 guidelines; this is defined as ≥100 WBC/microL in CSF (with or without trypanosomes in CSF). Such staging is important for guiding management, since <a class="drug drug_general" data-topicid="132112" href="/z/d/drug information/132112.html" rel="external">fexinidazole</a> is less efficacious in patients with CSF WBC ≥100 cells/microL. Clinical manifestations consistent with severe second-stage HAT are summarized in the table (<a class="graphic graphic_table graphicRef122839" href="/z/d/graphic/122839.html" rel="external">table 3</a>). (See <a class="local">'Second stage: Meningo-encephalitis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical approach to diagnosis – </strong>A definitive diagnosis of HAT requires demonstration of trypanosomes in body fluids (blood and/or CSF) or tissues (lymph node or chancre aspirate) via microscopy. (See <a class="local">'Clinical approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In endemic areas, the diagnosis of gambiense HAT should be suspected in individuals with epidemiologic exposure; in such cases, HAT is most frequently diagnosed in the context of screening; patients may or may not be symptomatic. Outside endemic areas, the diagnosis of gambiense HAT should be suspected in individuals with epidemiologic exposure (travel to an endemic area) in the setting of relevant signs or symptoms (early symptoms of fever, trypanosomal chancre or rash, headache, arthralgia, and lymphadenopathy; later symptoms of neurologic manifestations). (See <a class="local">'Gambiense HAT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Diagnostic evaluation for gambiense HAT begins with serologic assessment using a rapid diagnostic test; these include the card agglutination test for trypanosomiasis or rapid lateral flow tests (<a class="graphic graphic_algorithm graphicRef130705" href="/z/d/graphic/130705.html" rel="external">algorithm 1</a>). Patients with a positive serologic test should undergo confirmatory testing. Those with lymphadenopathy warrant lymph node aspiration with examination for parasites. If there is no lymphadenopathy, or the lymph node aspirate does not demonstrate trypanosomes, patients should undergo blood examination using a concentration technique; tools include microhematocrit centrifugation technique and mini anion-exchange centrifugation technique. Indications for CSF examination depend on findings of initial diagnostic evaluation, clinical manifestations, and the available treatment options. (See <a class="local">'Gambiense HAT'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The diagnosis of rhodesiense HAT should be suspected in individuals with epidemiologic exposure (travel to or residence in an endemic area), in the setting of relevant signs or symptoms (early symptoms of fever, trypanosomal chancre or rash, headache, arthralgia, lymphadenopathy; later symptoms of neurologic manifestations). The diagnosis of rhodesiense HAT can often be made via blood smear or chancre fluid; additional blood examination may be helpful in some cases (<a class="graphic graphic_algorithm graphicRef130501" href="/z/d/graphic/130501.html" rel="external">algorithm 2</a>). (See <a class="local">'Rhodesiense HAT'</a> above.)</p><p></p><p class="headingAnchor" id="H769240"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Dr. Karin Leder, MBBS, FRACP, PhD, MPH, DTMH, Dr. Peter Weller, MD, MACP, and Dr. August Stich, MD, MSc, DTMH, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. Geneva: World Health Organization; 2019. https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1 (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Kennedy PG. Human African trypanosomiasis of the CNS: current issues and challenges. J Clin Invest 2004; 113:496.</a></li><li><a class="nounderline abstract_t">Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. Lancet 2017; 390:2397.</a></li><li class="breakAll">World Health Organization. Trypanosomiasis, human African (sleeping sickness). https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness) (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Simarro PP, Cecchi G, Paone M, et al. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. Int J Health Geogr 2010; 9:57.</a></li><li><a class="nounderline abstract_t">Franco JR, Cecchi G, Priotto G, et al. Monitoring the elimination of human African trypanosomiasis: Update to 2016. PLoS Negl Trop Dis 2018; 12:e0006890.</a></li><li><a class="nounderline abstract_t">Franco JR, Cecchi G, Priotto G, et al. Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018. PLoS Negl Trop Dis 2020; 14:e0008261.</a></li><li><a class="nounderline abstract_t">Franco JR, Cecchi G, Paone M, et al. The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020. PLoS Negl Trop Dis 2022; 16:e0010047.</a></li><li><a class="nounderline abstract_t">Pepin J. Combination therapy for sleeping sickness: a wake-up call. J Infect Dis 2007; 195:311.</a></li><li><a class="nounderline abstract_t">Smith DH, Pepin J, Stich AH. Human African trypanosomiasis: an emerging public health crisis. Br Med Bull 1998; 54:341.</a></li><li><a class="nounderline abstract_t">Mhlanga JD. Sleeping sickness: perspectives in African trypanosomiasis. Sci Prog 1996; 79 ( Pt 3):183.</a></li><li><a class="nounderline abstract_t">Stich A, Abel PM, Krishna S. Human African trypanosomiasis. BMJ 2002; 325:203.</a></li><li><a class="nounderline abstract_t">Barrett MP. The rise and fall of sleeping sickness. Lancet 2006; 367:1377.</a></li><li class="breakAll">World Health Organization. Trypanosomiasis, human African (sleeping sickness). Available at: https://www.who.int/news-room/fact-sheets/detail/trypanosomiasis-human-african-(sleeping-sickness) (Accessed on May 23, 2023).</li><li><a class="nounderline abstract_t">Simarro PP, Franco JR, Cecchi G, et al. Human African trypanosomiasis in non-endemic countries (2000-2010). J Travel Med 2012; 19:44.</a></li><li><a class="nounderline abstract_t">Migchelsen SJ, Büscher P, Hoepelman AI, et al. Human African trypanosomiasis: a review of non-endemic cases in the past 20 years. Int J Infect Dis 2011; 15:e517.</a></li><li><a class="nounderline abstract_t">Ripamonti D, Massari M, Arici C, et al. African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers. Clin Infect Dis 2002; 34:E18.</a></li><li><a class="nounderline abstract_t">Moore DA, Edwards M, Escombe R, et al. African trypanosomiasis in travelers returning to the United Kingdom. Emerg Infect Dis 2002; 8:74.</a></li><li><a class="nounderline abstract_t">Jelinek T, Bisoffi Z, Bonazzi L, et al. Cluster of African trypanosomiasis in travelers to Tanzanian national parks. Emerg Infect Dis 2002; 8:634.</a></li><li><a class="nounderline abstract_t">Simarro PP, Cecchi G, Franco JR, et al. Monitoring the Progress towards the Elimination of Gambiense Human African Trypanosomiasis. PLoS Negl Trop Dis 2015; 9:e0003785.</a></li><li><a class="nounderline abstract_t">Informal Expert Group on Gambiense HAT Reservoirs, Büscher P, Bart JM, et al. Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination? Trends Parasitol 2018; 34:197.</a></li><li><a class="nounderline abstract_t">Camara M, Soumah AM, Ilboudo H, et al. Extravascular Dermal Trypanosomes in Suspected and Confirmed Cases of gambiense Human African Trypanosomiasis. Clin Infect Dis 2021; 73:12.</a></li><li><a class="nounderline abstract_t">Capewell P, Cren-Travaillé C, Marchesi F, et al. The skin is a significant but overlooked anatomical reservoir for vector-borne African trypanosomes. Elife 2016; 5.</a></li><li><a class="nounderline abstract_t">Malvy D, Chappuis F. Sleeping sickness. Clin Microbiol Infect 2011; 17:986.</a></li><li><a class="nounderline abstract_t">Lindner AK, Priotto G. The unknown risk of vertical transmission in sleeping sickness--a literature review. PLoS Negl Trop Dis 2010; 4:e783.</a></li><li><a class="nounderline abstract_t">World Health Organization. Control and surveillance of human African trypanosomiasis. World Health Organ Tech Rep Ser 2013; :1.</a></li><li><a class="nounderline abstract_t">Simon F, Mura M, Pagès F, et al. Urban transmission of human African trypanosomiasis, Gabon. Emerg Infect Dis 2012; 18:165.</a></li><li><a class="nounderline abstract_t">Alfituri OA, Quintana JF, MacLeod A, et al. To the Skin and Beyond: The Immune Response to African Trypanosomes as They Enter and Exit the Vertebrate Host. Front Immunol 2020; 11:1250.</a></li><li class="breakAll">World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: A roadmap for implementation. https://apps.who.int/iris/handle/10665/70809 (Accessed on January 20, 2023).</li><li class="breakAll">Pepin J, Donelson JE. African Trypanosomiasis (Sleeping Sickness). In: Tropical Infectious Diseases: Principles, Pathogens and Practice, 3rd ed, Guerrant R, Walker DH, Weller PF (Eds), Saunders Elsevier, Philadelphia 2011. p.682.</li><li><a class="nounderline abstract_t">Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P, et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003; 422:83.</a></li><li><a class="nounderline abstract_t">Pérez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005; 309:469.</a></li><li><a class="nounderline abstract_t">Vanhollebeke B, Truc P, Poelvoorde P, et al. Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I. N Engl J Med 2006; 355:2752.</a></li><li><a class="nounderline abstract_t">Pays E, Vanhollebeke B, Uzureau P, et al. The molecular arms race between African trypanosomes and humans. Nat Rev Microbiol 2014; 12:575.</a></li><li><a class="nounderline abstract_t">Kamoto K, Noyes H, Nambala P, et al. Association of APOL1 renal disease risk alleles with Trypanosoma brucei rhodesiense infection outcomes in the northern part of Malawi. PLoS Negl Trop Dis 2019; 13:e0007603.</a></li><li><a class="nounderline abstract_t">Hajduk SL. Antigenic variation during the developmental cycle of Trypanosoma brucei. J Protozool 1984; 31:41.</a></li><li><a class="nounderline abstract_t">Borst P, Rudenko G. Antigenic variation in African trypanosomes. Science 1994; 264:1872.</a></li><li><a class="nounderline abstract_t">Donelson JE. Antigenic variation and the African trypanosome genome. Acta Trop 2003; 85:391.</a></li><li class="breakAll">Pentreath VW, Kennedy PG. Pathogenesis of human African trypanosomiasis. In: The Trypanomiases, Mudlin I, Holmes PH, Miles MA (Eds), CABI Publishing, Reading, UK 2004.</li><li><a class="nounderline abstract_t">Chimelli L, Scaravilli F. Trypanosomiasis. Brain Pathol 1997; 7:599.</a></li><li class="breakAll">Burri C, Chappuis F, Brun R. Human African trypanosomiasis. In: Manson’s Tropical Diseases, 23rd, Farrar J, Hotez P, Junghanss T, et al (Eds), Saunders Ltd, 2014. p.606.</li><li><a class="nounderline abstract_t">Checchi F, Filipe JA, Haydon DT, et al. Estimates of the duration of the early and late stage of gambiense sleeping sickness. BMC Infect Dis 2008; 8:16.</a></li><li><a class="nounderline abstract_t">Checchi F, Funk S, Chandramohan D, et al. Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis. BMC Res Notes 2015; 8:292.</a></li><li><a class="nounderline abstract_t">Frean J, Sieling W, Pahad H, et al. Clinical management of East African trypanosomiasis in South Africa: Lessons learned. Int J Infect Dis 2018; 75:101.</a></li><li><a class="nounderline abstract_t">Urech K, Neumayr A, Blum J. Sleeping sickness in travelers - do they really sleep? PLoS Negl Trop Dis 2011; 5:e1358.</a></li><li><a class="nounderline abstract_t">Boatin BA, Wyatt GB, Wurapa FK, Bulsara MK. Use of symptoms and signs for diagnosis of Trypanosoma brucei rhodesiense trypanosomiasis by rural health personnel. Bull World Health Organ 1986; 64:389.</a></li><li><a class="nounderline abstract_t">Blum J, Schmid C, Burri C. Clinical aspects of 2541 patients with second stage human African trypanosomiasis. Acta Trop 2006; 97:55.</a></li><li><a class="nounderline abstract_t">Blum JA, Burri C, Hatz C, et al. Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis). Trop Med Int Health 2007; 12:1422.</a></li><li><a class="nounderline abstract_t">Jones IG, Lowenthal MN, Buyst H. Electrocardiographic changes in African trypanosomiasis caused by Trypanosoma brucei rhodesiense. Trans R Soc Trop Med Hyg 1975; 69:388.</a></li><li><a class="nounderline abstract_t">Poltera AA, Cox JN, Owor R. Pancarditis affecting the conducting system and all valves in human African trypanosomiasis. Br Heart J 1976; 38:827.</a></li><li><a class="nounderline abstract_t">Kennedy PG. The continuing problem of human African trypanosomiasis (sleeping sickness). Ann Neurol 2008; 64:116.</a></li><li><a class="nounderline abstract_t">Boa YF, Traore MA, Doua F, et al. [The different present-day clinical picture of human African trypanosomiasis caused by T. b. gambiense. Analysis of 300 cases from a focus in Daloa, Ivory Coast]. Bull Soc Pathol Exot Filiales 1988; 81:427.</a></li><li><a class="nounderline abstract_t">Duggan AJ, Hutchinson MP. Sleeping sickness in Europeans: a review of 109 cases. J Trop Med Hyg 1966; 69:124.</a></li><li><a class="nounderline abstract_t">Harms G, Feldmeier H. The impact of HIV infection on tropical diseases. Infect Dis Clin North Am 2005; 19:121.</a></li><li><a class="nounderline abstract_t">Wéry M, Mulumba PM, Lambert PH, Kazyumba L. Hematologic manifestations, diagnosis, and immunopathology of African trypanosomiasis. Semin Hematol 1982; 19:83.</a></li><li><a class="nounderline abstract_t">Chappuis F, Loutan L, Simarro P, et al. Options for field diagnosis of human african trypanosomiasis. Clin Microbiol Rev 2005; 18:133.</a></li><li><a class="nounderline abstract_t">Magnus E, Vervoort T, Van Meirvenne N. A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978; 58:169.</a></li><li><a class="nounderline abstract_t">Inojosa WO, Augusto I, Bisoffi Z, et al. Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies. BMJ 2006; 332:1479.</a></li><li><a class="nounderline abstract_t">Büscher P, Mertens P, Leclipteux T, et al. Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health 2014; 2:e359.</a></li><li><a class="nounderline abstract_t">Bisser S, Lumbala C, Nguertoum E, et al. Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection of Trypanosoma brucei gambiense Infection: A Multi-centric Prospective Study. PLoS Negl Trop Dis 2016; 10:e0004608.</a></li><li><a class="nounderline abstract_t">Lumbala C, Biéler S, Kayembe S, et al. Prospective evaluation of a rapid diagnostic test for Trypanosoma brucei gambiense infection developed using recombinant antigens. PLoS Negl Trop Dis 2018; 12:e0006386.</a></li><li><a class="nounderline abstract_t">Jamonneau V, Camara O, Ilboudo H, et al. Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa. PLoS Negl Trop Dis 2015; 9:e0003480.</a></li><li><a class="nounderline abstract_t">Boelaert M, Mukendi D, Bottieau E, et al. A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo. EBioMedicine 2018; 27:11.</a></li><li><a class="nounderline abstract_t">Compaoré CFA, Kaboré J, Ilboudo H, et al. Monitoring the elimination of gambiense human African trypanosomiasis in the historical focus of Batié, South-West Burkina Faso. Parasite 2022; 29:25.</a></li><li><a class="nounderline abstract_t">Geerts M, Van Reet N, Leyten S, et al. Trypanosoma brucei gambiense-iELISA: A Promising New Test for the Post-Elimination Monitoring of Human African Trypanosomiasis. Clin Infect Dis 2021; 73:e2477.</a></li><li><a class="nounderline abstract_t">Van Meirvenne N, Magnus E, Buscher P. Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense. Acta Trop 1995; 60:189.</a></li><li><a class="nounderline abstract_t">Simarro PP, Franco JR, Ndongo P. Field evaluation of several serological screening tests for sleeping sickness (T. b. gambiense). Bull Liais Doc OCEAC 1999; 32:28.</a></li><li><a class="nounderline abstract_t">Kegels G, Criel B, van Lerberghe W, et al. Screening for Trypanosoma brucei gambiense antibodies with the Indirect Fluorescent Antibody Test (IFAT). Effect of age and previous treatment. Ann Soc Belg Med Trop 1992; 72:271.</a></li><li><a class="nounderline abstract_t">Magnus E. Contribution à la standardisation du test d'immunofluorescence indirecte pour le diagnostic de la maladie du sommeil à Trypanosoma brucei gambiense. Tijdschr Belg Ver Lab Techn 1998; 15:321.</a></li><li><a class="nounderline abstract_t">Vervoort T, Magnus E, Van Meirvenne N. Enzyme-linked immunosorbent assay (ELISA) with variable antigen for serodiagnosis of T. B. gambiense trypanosomiasis. Ann Soc Belg Med Trop 1978; 58:177.</a></li><li><a class="nounderline abstract_t">Lejon V, Jamonneau V, Solano P, et al. Detection of trypanosome-specific antibodies in saliva, towards non-invasive serological diagnosis of sleeping sickness. Trop Med Int Health 2006; 11:620.</a></li><li><a class="nounderline abstract_t">Roffi J, Carrie J, Garre MT, Dedet JP. [Immunoenzymatic detection of human African trypanosomiasis using dried blood samples]. Bull Soc Pathol Exot Filiales 1980; 73:67.</a></li><li><a class="nounderline abstract_t">Mangenot M, Chaize J, Desfontaine M, et a;l. Intérêt de la technique ELISA pour le dépistage dans les foyers de trypanosomiase humaine africaine. Comparaison avec l'immunofluorescence. Méd Trop 1979; 39:527.</a></li><li><a class="nounderline abstract_t">Ruitenberg EJ, Buys J. Application of the enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of human African trypanosomiasis (sleeping sickness). Am J Trop Med Hyg 1977; 26:31.</a></li><li><a class="nounderline abstract_t">Voller A, Bidwell D, Bartlett A. A serological study on human Trypanosoma rhodesiense infections using a micro-scale enzyme linked immunosorbent assay. Tropenmed Parasitol 1975; 26:247.</a></li><li><a class="nounderline abstract_t">Bailey NM, Cunningham MP, Kimber CD. The indirect fluorescent antibody technique applied to dried blood, for use as a screening test in the diagnosis of human trypanosomiasis in Africa. Trans R Soc Trop Med Hyg 1967; 61:696.</a></li><li><a class="nounderline abstract_t">Dukes P, Rickman LR, Killick-Kendrick R, et al. A field comparison of seven diagnostic techniques for human trypanosomiasis in the Luangwa Valley, Zambia. Tropenmed Parasitol 1984; 35:141.</a></li><li><a class="nounderline abstract_t">Wellde BT, Chumo DA, Reardon MJ, et al. Diagnosis of Rhodesian sleeping sickness in the Lambwe Valley (1980-1984). Ann Trop Med Parasitol 1989; 83 Suppl 1:63.</a></li><li><a class="nounderline abstract_t">Miezan TW, Meda AH, Doua F, Cattand P. [Evaluation of the parasitologic technics used in the diagnosis of human Trypanosoma gambiense trypanosomiasis in the Ivory Coast]. Bull Soc Pathol Exot 1994; 87:101.</a></li><li><a class="nounderline abstract_t">Lutumba P, Robays J, Miaka C, et al. [Validity, cost and feasibility of the mAECT and CTC confirmation tests after diagnosis of African of sleeping sickness]. Trop Med Int Health 2006; 11:470.</a></li><li><a class="nounderline abstract_t">Camara M, Camara O, Ilboudo H, et al. Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test. Trop Med Int Health 2010; 15:796.</a></li><li><a class="nounderline abstract_t">Mumba Ngoyi D, Ali Ekangu R, Mumvemba Kodi MF, et al. Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness. PLoS Negl Trop Dis 2014; 8:e2954.</a></li><li><a class="nounderline abstract_t">Truc P, Aerts D, McNamara JJ, et al. Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of gambian trypanosomiasis. Trans R Soc Trop Med Hyg 1992; 86:627.</a></li><li><a class="nounderline abstract_t">Bailey JW, Smith DH. The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis. Trans R Soc Trop Med Hyg 1992; 86:630.</a></li><li><a class="nounderline abstract_t">Biéler S, Matovu E, Mitashi P, et al. Improved detection of Trypanosoma brucei by lysis of red blood cells, concentration and LED fluorescence microscopy. Acta Trop 2012; 121:135.</a></li><li><a class="nounderline abstract_t">Lumsden WH, Kimber CD, Dukes P, et al. Field diagnosis of sleeping sickness in the Ivory Coast. I. Comparison of the miniature anion-exchange/centrifugation technique with other protozoological methods. Trans R Soc Trop Med Hyg 1981; 75:242.</a></li><li><a class="nounderline abstract_t">Lumsden WH, Kimber CD, Evans DA, Doig SJ. Trypanosoma brucei: Miniature anion-exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use. Trans R Soc Trop Med Hyg 1979; 73:312.</a></li><li><a class="nounderline abstract_t">Büscher P, Mumba Ngoyi D, Kaboré J, et al. Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and Modified Single Centrifugation (MSC) for sleeping sickness diagnosis and staging. PLoS Negl Trop Dis 2009; 3:e471.</a></li><li class="breakAll">World Health Organization. Control and surveillance of human African trypanosomiasis: report of a WHO expert committee. https://apps.who.int/iris/handle/10665/95732 (Accessed on January 23, 2023).</li><li><a class="nounderline abstract_t">Miézan TW, Meda HA, Doua F, et al. Single centrifugation of cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of trypanosomes. Trans R Soc Trop Med Hyg 2000; 94:293.</a></li><li><a class="nounderline abstract_t">Kazumba LM, Kaka JT, Ngoyi DM, Tshala-Katumbay D. Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo. PLoS Negl Trop Dis 2018; 12:e0006504.</a></li><li><a class="nounderline abstract_t">Lejon V, Büscher P. Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Trop Med Int Health 2005; 10:395.</a></li><li><a class="nounderline abstract_t">Lejon V, Reiber H, Legros D, et al. Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis. J Infect Dis 2003; 187:1475.</a></li><li><a class="nounderline abstract_t">Bain BJ. Russell bodies and Mott cells. Am J Hematol 2009; 84:516.</a></li><li class="breakAll">Krishna S, Stich A. Human African Trypanosomiasis. In: Hunter's Tropical Medicine and Emerging Infections, 9th ed, Magill AJ, Maguire JH, Ryan ET, Solomon T (Eds), Elsevier, 2012.</li><li><a class="nounderline abstract_t">Tiberti N, Hainard A, Lejon V, et al. Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness. PLoS One 2012; 7:e40909.</a></li><li><a class="nounderline abstract_t">Lejon V, Sindic CJ, Van Antwerpen MP, et al. Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response. Eur J Neurol 2003; 10:711.</a></li><li><a class="nounderline abstract_t">Kager PA, Schipper HG, Stam J, Majoie CB. Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature. Am J Trop Med Hyg 2009; 80:947.</a></li><li><a class="nounderline abstract_t">Braakman HM, van de Molengraft FJ, Hubert WW, Boerman DH. Lethal African trypanosomiasis in a traveler: MRI and neuropathology. Neurology 2006; 66:1094.</a></li><li><a class="nounderline abstract_t">Xiao Z, Dong A, Wang Y. FDG PET/CT in a Case of Human African Trypanosomiasis (Sleeping Sickness). Clin Nucl Med 2018; 43:619.</a></li><li><a class="nounderline abstract_t">Jamonneau V, Solano P, Garcia A, et al. Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire. Trop Med Int Health 2003; 8:589.</a></li><li><a class="nounderline abstract_t">Wastling SL, Picozzi K, Kakembo AS, Welburn SC. LAMP for human African trypanosomiasis: a comparative study of detection formats. PLoS Negl Trop Dis 2010; 4:e865.</a></li><li><a class="nounderline abstract_t">Njiru ZK, Traub R, Ouma JO, et al. Detection of Group 1 Trypanosoma brucei gambiense by loop-mediated isothermal amplification. J Clin Microbiol 2011; 49:1530.</a></li><li><a class="nounderline abstract_t">Büscher P, Deborggraeve S. How can molecular diagnostics contribute to the elimination of human African trypanosomiasis? Expert Rev Mol Diagn 2015; 15:607.</a></li><li><a class="nounderline abstract_t">Mitashi P, Hasker E, Ngoyi DM, et al. Diagnostic accuracy of loopamp Trypanosoma brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples. PLoS Negl Trop Dis 2013; 7:e2504.</a></li><li><a class="nounderline abstract_t">Ngay Lukusa I, Van Reet N, Mumba Ngoyi D, et al. Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study. EBioMedicine 2022; 86:104376.</a></li><li><a class="nounderline abstract_t">Van Reet N, Patient Pyana P, Dehou S, et al. Single nucleotide polymorphisms and copy-number variations in the Trypanosoma brucei repeat (TBR) sequence can be used to enhance amplification and genotyping of Trypanozoon strains. PLoS One 2021; 16:e0258711.</a></li><li><a class="nounderline abstract_t">Sima N, Dujeancourt-Henry A, Perlaza BL, et al. SHERLOCK4HAT: A CRISPR-based tool kit for diagnosis of Human African Trypanosomiasis. EBioMedicine 2022; 85:104308.</a></li><li><a class="nounderline abstract_t">Wamboga C, Matovu E, Bessell PR, et al. Enhanced passive screening and diagnosis for gambiense human African trypanosomiasis in north-western Uganda - Moving towards elimination. PLoS One 2017; 12:e0186429.</a></li></ol></div><div id="topicVersionRevision">Topic 5697 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : WHO interim guidelines for the treatment of gambiense human African trypanosomiasis. Geneva: World Health Organization; 2019. https://apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1 (Accessed on January 23, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14966556" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Human African trypanosomiasis of the CNS: current issues and challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673422" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673422" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21040555" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30521525" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Monitoring the elimination of human African trypanosomiasis: Update to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32437391" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Monitoring the elimination of human African trypanosomiasis at continental and country level: Update to 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35041668" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17205466" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Combination therapy for sleeping sickness: a wake-up call.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9830201" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Human African trypanosomiasis: an emerging public health crisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8973165" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sleeping sickness: perspectives in African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12142311" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650633" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The rise and fall of sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16650633" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The rise and fall of sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22221811" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Human African trypanosomiasis in non-endemic countries (2000-2010).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21683638" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Human African trypanosomiasis: a review of non-endemic cases in the past 20 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11731969" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : African sleeping sickness in tourists returning from Tanzania: the first 2 Italian cases from a small outbreak among European travelers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11749752" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : African trypanosomiasis in travelers returning to the United Kingdom.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12023923" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cluster of African trypanosomiasis in travelers to Tanzanian national parks.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26056823" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Monitoring the Progress towards the Elimination of Gambiense Human African Trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29396200" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Do Cryptic Reservoirs Threaten Gambiense-Sleeping Sickness Elimination?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32638003" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Extravascular Dermal Trypanosomes in Suspected and Confirmed Cases of gambiense Human African Trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27653219" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The skin is a significant but overlooked anatomical reservoir for vector-borne African trypanosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21722252" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21200416" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : The unknown risk of vertical transmission in sleeping sickness--a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552089" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Control and surveillance of human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22261276" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Urban transmission of human African trypanosomiasis, Gabon.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32595652" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : To the Skin and Beyond: The Immune Response to African Trypanosomes as They Enter and Exit the Vertebrate Host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32595652" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : To the Skin and Beyond: The Immune Response to African Trypanosomes as They Enter and Exit the Vertebrate Host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32595652" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : To the Skin and Beyond: The Immune Response to African Trypanosomes as They Enter and Exit the Vertebrate Host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12621437" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Apolipoprotein L-I is the trypanosome lytic factor of human serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16020735" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17192540" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Human Trypanosoma evansi infection linked to a lack of apolipoprotein L-I.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24975321" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The molecular arms race between African trypanosomes and humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31412021" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Association of APOL1 renal disease risk alleles with Trypanosoma brucei rhodesiense infection outcomes in the northern part of Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6204043" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antigenic variation during the developmental cycle of Trypanosoma brucei.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7516579" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Antigenic variation in African trypanosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12659976" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Antigenic variation and the African trypanosome genome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12659976" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antigenic variation and the African trypanosome genome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9034568" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9034568" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18261232" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Estimates of the duration of the early and late stage of gambiense sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26140922" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153486" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Clinical management of East African trypanosomiasis in South Africa: Lessons learned.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22069503" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Sleeping sickness in travelers - do they really sleep?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3490318" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Use of symptoms and signs for diagnosis of Trypanosoma brucei rhodesiense trypanosomiasis by rural health personnel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16157286" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Clinical aspects of 2541 patients with second stage human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18076548" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Sleeping hearts: the role of the heart in sleeping sickness (human African trypanosomiasis).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1216299" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Electrocardiographic changes in African trypanosomiasis caused by Trypanosoma brucei rhodesiense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/973907" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Pancarditis affecting the conducting system and all valves in human African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18756506" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The continuing problem of human African trypanosomiasis (sleeping sickness).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2848637" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : [The different present-day clinical picture of human African trypanosomiasis caused by T. b. gambiense. Analysis of 300 cases from a focus in Daloa, Ivory Coast].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5940665" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Sleeping sickness in Europeans: a review of 109 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701550" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The impact of HIV infection on tropical diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7041266" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Hematologic manifestations, diagnosis, and immunopathology of African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15653823" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Options for field diagnosis of human african trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/747425" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A card-agglutination test with stained trypanosomes (C.A.T.T.) for the serological diagnosis of T. B. gambiense trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16777858" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Diagnosing human African trypanosomiasis in Angola using a card agglutination test: observational study of active and passive case finding strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25103304" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Sensitivity and specificity of HAT Sero-K-SeT, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27058033" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Sensitivity and Specificity of a Prototype Rapid Diagnostic Test for the Detection of Trypanosoma brucei gambiense Infection: A Multi-centric Prospective Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590116" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Prospective evaluation of a rapid diagnostic test for Trypanosoma brucei gambiense infection developed using recombinant antigens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25642701" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Accuracy of individual rapid tests for serodiagnosis of gambiense sleeping sickness in West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29246478" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A Phase III Diagnostic Accuracy Study of a Rapid Diagnostic Test for Diagnosis of Second-Stage Human African Trypanosomiasis in the Democratic Republic of the Congo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35543528" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Monitoring the elimination of gambiense human African trypanosomiasis in the historical focus of Batié, South-West Burkina Faso.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32856049" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Trypanosoma brucei gambiense-iELISA: A Promising New Test for the Post-Elimination Monitoring of Human African Trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8907397" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Evaluation of variant specific trypanolysis tests for serodiagnosis of human infections with Trypanosoma brucei gambiense.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Field evaluation of several serological screening tests for sleeping sickness (T. b. gambiense)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1292423" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Screening for Trypanosoma brucei gambiense antibodies with the Indirect Fluorescent Antibody Test (IFAT). Effect of age and previous treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Contributionàla standardisation du test d'immunofluorescence indirecte pour le diagnostic de la maladie du sommeilàTrypanosoma brucei gambiense</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/747426" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Enzyme-linked immunosorbent assay (ELISA) with variable antigen for serodiagnosis of T. B. gambiense trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16640614" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Detection of trypanosome-specific antibodies in saliva, towards non-invasive serological diagnosis of sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7418124" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : [Immunoenzymatic detection of human African trypanosomiasis using dried blood samples].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Intérêt de la technique ELISA pour le dépistage dans les foyers de trypanosomiase humaine africaine. Comparaison avec l'immunofluorescence</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/320895" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Application of the enzyme-linked immunosorbent assay (ELISA) for the serodiagnosis of human African trypanosomiasis (sleeping sickness).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1099749" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : A serological study on human Trypanosoma rhodesiense infections using a micro-scale enzyme linked immunosorbent assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4168062" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The indirect fluorescent antibody technique applied to dried blood, for use as a screening test in the diagnosis of human trypanosomiasis in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6208660" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : A field comparison of seven diagnostic techniques for human trypanosomiasis in the Luangwa Valley, Zambia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2694986" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Diagnosis of Rhodesian sleeping sickness in the Lambwe Valley (1980-1984).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8061525" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : [Evaluation of the parasitologic technics used in the diagnosis of human Trypanosoma gambiense trypanosomiasis in the Ivory Coast].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16553930" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : [Validity, cost and feasibility of the mAECT and CTC confirmation tests after diagnosis of African of sleeping sickness].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20497407" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Sleeping sickness diagnosis: use of buffy coats improves the sensitivity of the mini anion exchange centrifugation test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24921941" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Performance of parasitological and molecular techniques for the diagnosis and surveillance of gambiense sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1287920" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Direct isolation in vitro of Trypanosoma brucei from man and other animals, and its potential value for the diagnosis of gambian trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1287921" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : The use of the acridine orange QBC technique in the diagnosis of African trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22079374" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Improved detection of Trypanosoma brucei by lysis of red blood cells, concentration and LED fluorescence microscopy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6272458" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Field diagnosis of sleeping sickness in the Ivory Coast. I. Comparison of the miniature anion-exchange/centrifugation technique with other protozoological methods.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/473329" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Trypanosoma brucei: Miniature anion-exchange centrifugation technique for detection of low parasitaemias: Adaptation for field use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19936296" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and Modified Single Centrifugation (MSC) for sleeping sickness diagnosis and staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19936296" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Improved Models of Mini Anion Exchange Centrifugation Technique (mAECT) and Modified Single Centrifugation (MSC) for sleeping sickness diagnosis and staging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10975002" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Single centrifugation of cerebrospinal fluid in a sealed pasteur pipette for simple, rapid and sensitive detection of trypanosomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29897919" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: A critical appraisal of 23 years of experience in the Democratic Republic of Congo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15860085" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12717630" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Intrathecal immune response pattern for improved diagnosis of central nervous system involvement in trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384941" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Russell bodies and Mott cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384941" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Russell bodies and Mott cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22815865" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Cerebrospinal fluid neopterin as marker of the meningo-encephalitic stage of Trypanosoma brucei gambiense sleeping sickness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14641518" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Human African trypanosomiasis: quantitative and qualitative assessment of intrathecal immune response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19478256" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Magnetic resonance imaging findings in human African trypanosomiasis: a four-year follow-up study in a patient and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16606924" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Lethal African trypanosomiasis in a traveler: MRI and neuropathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29863573" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : FDG PET/CT in a Case of Human African Trypanosomiasis (Sleeping Sickness).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828540" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Stage determination and therapeutic decision in human African trypanosomiasis: value of polymerase chain reaction and immunoglobulin M quantification on the cerebrospinal fluid of sleeping sickness patients in Côte d'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21072228" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : LAMP for human African trypanosomiasis: a comparative study of detection formats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21307218" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Detection of Group 1 Trypanosoma brucei gambiense by loop-mediated isothermal amplification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25786994" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : How can molecular diagnostics contribute to the elimination of human African trypanosomiasis?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24147176" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Diagnostic accuracy of loopamp Trypanosoma brucei detection kit for diagnosis of human African trypanosomiasis in clinical samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36436279" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Trypanosome spliced leader RNA for diagnosis of acoziborole treatment outcome in gambiense human African trypanosomiasis: A longitudinal follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34695154" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Single nucleotide polymorphisms and copy-number variations in the Trypanosoma brucei repeat (TBR) sequence can be used to enhance amplification and genotyping of Trypanozoon strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36374773" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : SHERLOCK4HAT: A CRISPR-based tool kit for diagnosis of Human African Trypanosomiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29023573" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Enhanced passive screening and diagnosis for gambiense human African trypanosomiasis in north-western Uganda - Moving towards elimination.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
